Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS an… (NCT07390851) | Clinical Trial Compass
RecruitingNot Applicable
Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.
Egypt28 participantsStarted 2025-11-26
Plain-language summary
Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 18 and 70 years.
✓. Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).
✓. Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).
✓. Pain duration ≥ 3 months.
✓. Pain intensity ≥ 4 on the Visual Analog Scale (VAS).
✓. Noprior trigger point injection in the affected area within the past 3 months.
✓. Ability and willingness to provide informed consent.
✓. Compliance with study visits and procedures
Exclusion criteria
✕. Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.
✕. Current use of anticoagulants or history of bleeding disorders.
✕. Systemic or local infection at or near the injection site.
✕. History of fibromyalgia, central pain syndromes, or cancer-related pain.
✕. Major psychiatric illnesses (e.g., schizophrenia, severe depression).
✕. Recent surgery or trauma to the head, neck, or upper back (\<6 months).